NOX2 has been suggested as a potential target in the development of a therapy against chronic myeloid leukemia (CML) and glioblastoma, as the resistance of CML stem cells and patient-derived glioblastoma stem cells to tyrosine kinase inhibitors seem to be mediated through the NOX2/Egr1/Fyn axis [143]. This evidence concerns the gene FYN and chronic myelogenous leukemia, BCR-ABL1 positive.